What ||| S:0 E:4 ||| WP
's  ||| S:4 E:7 ||| VBZ
new  ||| S:7 E:11 ||| JJ
in  ||| S:11 E:14 ||| IN
clinical  ||| S:14 E:23 ||| JJ
dermatology ||| S:23 E:34 ||| NN
?  ||| S:34 E:36 ||| .
This  ||| S:36 E:41 ||| DT
year  ||| S:41 E:46 ||| NN
more  ||| S:46 E:51 ||| RBR
than  ||| S:51 E:56 ||| IN
3000  ||| S:56 E:61 ||| CD
medical  ||| S:61 E:69 ||| JJ
articles  ||| S:69 E:78 ||| NNS
referenced  ||| S:78 E:89 ||| VBN
in  ||| S:89 E:92 ||| IN
PubMed  ||| S:92 E:99 ||| JJ
concerned  ||| S:99 E:109 ||| JJ
dermatology ||| S:109 E:120 ||| NN
.  ||| S:120 E:122 ||| .
Our  ||| S:122 E:126 ||| PRP$
critical  ||| S:126 E:135 ||| JJ
analysis  ||| S:135 E:144 ||| NN
covers  ||| S:144 E:151 ||| VBZ
different  ||| S:151 E:161 ||| JJ
fields  ||| S:161 E:168 ||| NNS
of  ||| S:168 E:171 ||| IN
dermatology ||| S:171 E:182 ||| NNS
:  ||| S:182 E:184 ||| :
including  ||| S:184 E:194 ||| VBG
epidemiology ||| S:194 E:206 ||| NN
,  ||| S:206 E:208 ||| ,
clinical ||| S:208 E:216 ||| JJ
,  ||| S:216 E:218 ||| ,
diagnostic  ||| S:218 E:229 ||| JJ
and  ||| S:229 E:233 ||| CC
prognostic  ||| S:233 E:244 ||| JJ
factors ||| S:244 E:251 ||| NNS
.  ||| S:251 E:253 ||| .
AIDS  ||| S:253 E:258 ||| NNP
is  ||| S:258 E:261 ||| VBZ
30  ||| S:261 E:264 ||| CD
years  ||| S:264 E:270 ||| NNS
old  ||| S:270 E:274 ||| JJ
and  ||| S:274 E:278 ||| CC
the  ||| S:278 E:282 ||| DT
national  ||| S:282 E:291 ||| JJ
HIV ||| S:291 E:294 ||| NNP
/ ||| S:294 E:295 ||| NNP
AIDS  ||| S:295 E:300 ||| NNP
plan  ||| S:300 E:305 ||| NN
for  ||| S:305 E:309 ||| IN
2010-2014  ||| S:309 E:319 ||| NNP
recommends  ||| S:319 E:330 ||| VBZ
generalized  ||| S:330 E:342 ||| JJ
screening  ||| S:342 E:352 ||| NN
facilitated  ||| S:352 E:364 ||| NN
by  ||| S:364 E:367 ||| IN
the  ||| S:367 E:371 ||| DT
introduction  ||| S:371 E:384 ||| NN
of  ||| S:384 E:387 ||| IN
rapid  ||| S:387 E:393 ||| JJ
tests  ||| S:393 E:399 ||| NNS
for  ||| S:399 E:403 ||| IN
diagnostic  ||| S:403 E:414 ||| JJ
orientation ||| S:414 E:425 ||| NN
.  ||| S:425 E:427 ||| .
In  ||| S:427 E:430 ||| IN
infectious  ||| S:430 E:441 ||| JJ
diseases ||| S:441 E:449 ||| NNS
,  ||| S:449 E:451 ||| ,
novelties  ||| S:451 E:461 ||| JJ
concern  ||| S:461 E:469 ||| NN
polyomavirus ||| S:469 E:481 ||| NN
,  ||| S:481 E:483 ||| ,
HTLV-1 ||| S:483 E:489 ||| NNP
,  ||| S:489 E:491 ||| ,
leprosy ||| S:491 E:498 ||| NN
,  ||| S:498 E:500 ||| ,
staphylococcus  ||| S:500 E:515 ||| JJ
infections ||| S:515 E:525 ||| NNS
,  ||| S:525 E:527 ||| ,
resistance  ||| S:527 E:538 ||| NN
to  ||| S:538 E:541 ||| TO
antibiotics  ||| S:541 E:553 ||| VB
and  ||| S:553 E:557 ||| CC
scabies ||| S:557 E:564 ||| NN
.  ||| S:564 E:566 ||| .
Diseases  ||| S:566 E:575 ||| NNS
of  ||| S:575 E:578 ||| IN
the  ||| S:578 E:582 ||| DT
scalp  ||| S:582 E:588 ||| JJ
consecutive  ||| S:588 E:600 ||| JJ
to  ||| S:600 E:603 ||| TO
practices  ||| S:603 E:613 ||| NNS
of  ||| S:613 E:616 ||| IN
black  ||| S:616 E:622 ||| JJ
women  ||| S:622 E:628 ||| NNS
hairstyles  ||| S:628 E:639 ||| NN
were  ||| S:639 E:644 ||| VBD
the  ||| S:644 E:648 ||| DT
subject  ||| S:648 E:656 ||| NN
of  ||| S:656 E:659 ||| IN
important  ||| S:659 E:669 ||| JJ
articles ||| S:669 E:677 ||| NNS
.  ||| S:677 E:679 ||| .
There  ||| S:679 E:685 ||| EX
were  ||| S:685 E:690 ||| VBD
two  ||| S:690 E:694 ||| CD
important  ||| S:694 E:704 ||| JJ
developments  ||| S:704 E:717 ||| NNS
in  ||| S:717 E:720 ||| IN
acne ||| S:720 E:724 ||| NN
:  ||| S:724 E:726 ||| :
first ||| S:726 E:731 ||| RB
,  ||| S:731 E:733 ||| ,
a  ||| S:733 E:735 ||| DT
simplified  ||| S:735 E:746 ||| NN
and  ||| S:746 E:750 ||| CC
more  ||| S:750 E:755 ||| RBR
operational  ||| S:755 E:767 ||| JJ
classification ||| S:767 E:781 ||| NN
,  ||| S:781 E:783 ||| ,
secondly  ||| S:783 E:792 ||| VBG
a  ||| S:792 E:794 ||| DT
suicidal  ||| S:794 E:803 ||| JJ
risk  ||| S:803 E:808 ||| NN
associated  ||| S:808 E:819 ||| VBN
with  ||| S:819 E:824 ||| IN
severe  ||| S:824 E:831 ||| JJ
forms ||| S:831 E:836 ||| NNS
.  ||| S:836 E:838 ||| .
Lymphocyte  ||| S:838 E:849 ||| NNP
Th-17  ||| S:849 E:855 ||| NNP
immunity  ||| S:855 E:864 ||| NN
is  ||| S:864 E:867 ||| VBZ
involved  ||| S:867 E:876 ||| VBN
in  ||| S:876 E:879 ||| IN
clinical  ||| S:879 E:888 ||| JJ
phenomena  ||| S:888 E:898 ||| NNS
either  ||| S:898 E:905 ||| CC
by  ||| S:905 E:908 ||| IN
excess  ||| S:908 E:915 ||| JJ
( ||| S:915 E:916 ||| -LRB-
genetic  ||| S:916 E:924 ||| JJ
or  ||| S:924 E:927 ||| CC
drug ||| S:927 E:931 ||| NN
)  ||| S:931 E:933 ||| -RRB-
or  ||| S:933 E:936 ||| CC
default  ||| S:936 E:944 ||| NN
( ||| S:944 E:945 ||| -LRB-
genetic  ||| S:945 E:953 ||| JJ
causes ||| S:953 E:959 ||| NNS
) ||| S:959 E:960 ||| -RRB-
.  ||| S:960 E:962 ||| .
Allergology ||| S:962 E:973 ||| NNP
:  ||| S:973 E:975 ||| :
in  ||| S:975 E:978 ||| IN
several  ||| S:978 E:986 ||| JJ
studies ||| S:986 E:993 ||| NNS
,  ||| S:993 E:995 ||| ,
false  ||| S:995 E:1001 ||| JJ
negative  ||| S:1001 E:1010 ||| JJ
patch  ||| S:1010 E:1016 ||| NN
tests  ||| S:1016 E:1022 ||| NNS
have  ||| S:1022 E:1027 ||| VBP
been  ||| S:1027 E:1032 ||| VBN
published ||| S:1032 E:1041 ||| VBN
.  ||| S:1041 E:1043 ||| .
The  ||| S:1043 E:1047 ||| DT
natural  ||| S:1047 E:1055 ||| JJ
history  ||| S:1055 E:1063 ||| NN
of  ||| S:1063 E:1066 ||| IN
nevi  ||| S:1066 E:1071 ||| NN
is  ||| S:1071 E:1074 ||| VBZ
specified  ||| S:1074 E:1084 ||| VBN
by  ||| S:1084 E:1087 ||| IN
three  ||| S:1087 E:1093 ||| CD
important  ||| S:1093 E:1103 ||| JJ
articles ||| S:1103 E:1111 ||| NNS
.  ||| S:1111 E:1113 ||| .
Serological  ||| S:1113 E:1125 ||| JJ
tests  ||| S:1125 E:1131 ||| NNS
to  ||| S:1131 E:1134 ||| TO
practice  ||| S:1134 E:1143 ||| VB
in  ||| S:1143 E:1146 ||| IN
cases  ||| S:1146 E:1152 ||| NNS
of  ||| S:1152 E:1155 ||| IN
dermatomyositis  ||| S:1155 E:1171 ||| NN
and  ||| S:1171 E:1175 ||| CC
bullous  ||| S:1175 E:1183 ||| JJ
pemphigoid  ||| S:1183 E:1194 ||| NNS
are  ||| S:1194 E:1198 ||| VBP
specified ||| S:1198 E:1207 ||| VBN
.  ||| S:1207 E:1209 ||| .
